Lilly’s GLP-1 Agonist Delivers
Eli Lilly and Company (NYSE:LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study. Dulaglutide is a glucagon-like peptide 1 (GLP-1) analog which is being developed for the once-weekly treatment of type II diabetes. Results from the phase II, [...]
Eli Lilly and Company (NYSE:LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study. Dulaglutide is a glucagon-like peptide 1 (GLP-1) analog which is being developed for the once-weekly treatment of type II diabetes.
Results from the phase II, randomized, double-blind, placebo-controlled, 26-week, parallel study showed that dulaglutide achieved non-inferiority after 16 weeks for mean … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards